好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cerebrospinal Fluid AD Biomarkers and Regional [18F]-Flortaucipir Uptake in Lewy Body Disorders
Movement Disorders
S10 - Biomarkers in Movement Disorders (4:58 PM-5:09 PM)
009

Half of LBD patients have moderate/severe Alzheimer’s disease (AD) pathology at autopsy, associated with poor prognosis. In vivo detection of tau pathology by [18F]-flortaucipir may provide regional specificity to compliment CSF tau biomarkers in LBD.

To examine regional uptake of [18F]-flortaucipir (formerly [18F]-AV1451) in Lewy body disorders (LBD: dementia with Lewy bodies (DLB) and Parkinson’s disease (PD)) and its association with cerebrospinal fluid (CSF) total tau (t-tau) and phospho-tau (p-tau).
Twenty patients with LBD and cognitive impairment (DLB=15, PD with MCI/Dementia=5) underwent [18F]-flortaucipir PET imaging.  CSF Abeta42, p-tau, t-tau were analyzed using a Luminex platform and AlzBio3 immunoassay reagents (n=19/20).  The LBD cohort was divided using an established Abeta42 cut-off=191pg/ml (LBD+Aβ=11, LBD-Aβ=8).  Fifteen amyloid-PET-negative healthy controls (HC-Aβ) and 12 matched amyloid-PET-positive patients from ADNI (AD/Aβ+MCI) were comparators. Images were preprocessed using ANTs software with partial volume correction. Voxel-wise t-tests (uncorrected, p<0.05, k=0) and regional SUVRs using a whole cerebellar reference were compared across groups.  Mean cortical SUVR was correlated with CSF t-tau and p-tau using linear regression co-varying for sex and age.
In voxel-wise analysis, LBD+Aβ had increased [18F]-flortaucipir uptake in frontal, parietal, and occipital regions compared to HC-Aβ, while uptake in LBD-Aβ was similar to HC-Aβ.  LBD+Aβ had forty-one regions with increased SUVR compared to HC-Aβ, whereas LBD-Aβ had three. In voxel-wise analysis, AD/Aβ+MCI had higher uptake than LBD+Aβ in regions of all lobes but LBD+Aβ had higher uptake in areas of the precentral gyrus.  Mean cortical SUVR associated with CSF t-tau (Beta=0.40,p=0.049) but not p-tau (Beta=0.27,p=0.2) in the LBD cohort.
In LBD, patients with amyloid-positive CSF have [18F]-flortaucipir uptake that is increased compared to controls, generally less than AD/Aβ+MCI except for unique areas of increased precentral gyrus uptake.  In LBD, [18F]-flortaucipir uptake correlates with CSF t-tau and adds important information about the regional distribution of potential tau pathology.
Authors/Disclosures
David G. Coughlin, MD (University of California San Diego)
PRESENTER 		The institution of Dr. Coughlin has received research support from 好色先生. The institution of Dr. Coughlin has received research support from NIA. The institution of Dr. Coughlin has received research support from NINDS.
Jeffrey S. Phillips, PhD (Penn FTD Center, Department of Neurology) No disclosure on file
Emily Roll No disclosure on file
David A. Wolk, MD, FAAN (University of Pennsylvania) Dr. Wolk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Wolk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Functional Neuromodulation. Dr. Wolk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GSK. The institution of Dr. Wolk has received research support from Biogen. Dr. Wolk has received publishing royalties from a publication relating to health care. Dr. Wolk has received personal compensation in the range of $5,000-$9,999 for serving as a CME speaker with Eli Lilly.
No disclosure on file
Ilya Nasrallah, MD, PhD Dr. Nasrallah has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Nasrallah has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Nasrallah has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. Dr. Nasrallah has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Cassiday Schade LLP. The institution of Dr. Nasrallah has received research support from NIH. The institution of Dr. Nasrallah has received research support from ASNR.
Sanjeev Vaishnavi, MD, PhD (University of Pennsylvania) The institution of Dr. Vaishnavi has received research support from Novartis.
Andrew D. Siderowf, MD Dr. Siderowf has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer-Ingelheim. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for askbio. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for capsida. Dr. Siderowf has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Parkinson Study Group. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theravance. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prilenia. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Wave. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurogastrix. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prevail. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alerity. Dr. Siderowf has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Clintrex. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Inhibikase. Dr. Siderowf has a non-compensated relationship as a Scientific Advisory Board with NeuroPacs that is relevant to AAN interests or activities.
Daniel Weintraub Daniel Weintraub has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Clintrex. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scion. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunovion. Daniel Weintraub has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Modality.ai. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevel. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CuraSen. Daniel Weintraub has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer Ingelheim. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Daniel Weintraub has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Movement Disorder Society. The institution of Daniel Weintraub has received research support from NIH. The institution of Daniel Weintraub has received research support from Fox Foundation. The institution of Daniel Weintraub has received research support from IPMDS. Daniel Weintraub has received intellectual property interests from a discovery or technology relating to health care.
Leslie M. Shaw, PhD (Perelman School of Med, U of PA) Dr. Shaw has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Shaw has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Shaw has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Shaw has received research support from NIA. The institution of Dr. Shaw has received research support from MJ Fox foundation for Parkinsons Research.
John Q. Trojanowski, MD, PhD (University of PA School of Med) Dr. Trojanowski has nothing to disclose.
Murray Grossman, MD, FAAN (University of Pennsylvania) Dr. Grossman has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. The institution of Dr. Grossman has received research support from NIH.
David Irwin, MD (University of Pennsylvania) The institution of Dr. Irwin has received research support from NIH. The institution of Dr. Irwin has received research support from Prevail. The institution of Dr. Irwin has received research support from Passage Bio. The institution of Dr. Irwin has received research support from Alector. The institution of Dr. Irwin has received research support from Transposon. The institution of Dr. Irwin has received research support from Denali.
Corey McMillan, PhD (University of Pennsylvania) Dr. McMillan has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. McMillan has received research support from Biogen. The institution of Dr. McMillan has received research support from NIH.